<?xml version='1.0' encoding='utf-8'?>
<document id="27859472"><sentence text="Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma."><entity charOffset="10-22" id="DDI-PubMed.27859472.s1.e0" text="ketoconazole" /></sentence><sentence text="To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax"><entity charOffset="70-82" id="DDI-PubMed.27859472.s2.e0" text="ketoconazole" /></sentence><sentence text="" /><sentence text="Twelve patients with non-Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open-label, fixed-sequence study" /><sentence text=" Patients received a single 50 mg dose of venetoclax orally on Day 1 and Day 8, and a 400 mg once daily dose of ketoconazole on Days 5-11"><entity charOffset="112-124" id="DDI-PubMed.27859472.s5.e0" text="ketoconazole" /></sentence><sentence text=" Blood samples were collected predose and up to 96 h after each venetoclax dose on Day 1 and Day 8" /><sentence text="" /><sentence text="Eleven patients had evaluable pharmacokinetic data and were therefore included in the statistical analyses" /><sentence text=" Compared to administration of a single 50 mg dose of venetoclax alone, ketoconazole increased the venetoclax mean maximum observed plasma concentration (Cmax ) and area under the plasma concentration-time curve from time 0 to infinity (AUC∞ ) by 2"><entity charOffset="72-84" id="DDI-PubMed.27859472.s9.e0" text="ketoconazole" /></sentence><sentence text="3-fold (90% confidence interval [CI]: 2" /><sentence text="0-2" /><sentence text="7) and 6" /><sentence text="4-fold (90% CI: 4" /><sentence text="5-9" /><sentence text="2; range: 2- to 12-fold), respectively" /><sentence text="" /><sentence text="Coadministration of venetoclax with multiple doses of ketoconazole resulted in a significant increase of venetoclax exposures, strongly suggesting that CYP3A plays a major role in elimination of venetoclax in patients"><entity charOffset="54-66" id="DDI-PubMed.27859472.s17.e0" text="ketoconazole" /></sentence><sentence text=" These results suggest the need to avoid concomitant use with strong and moderate inhibitors or inducers of CYP3A during the venetoclax ramp-up phase in chronic lymphocytic leukaemia (CLL) patients" /><sentence text=" For patients who have completed the ramp-up phase, a modification in venetoclax dose for use with strong and moderate inhibitors or inducers of CYP3A is recommended" /><sentence text="" /></document>